WHO recommendations on antiplatelet agents for the prevention of pre-eclampsia
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
World Health Organization
Abstract
Description
viii, 70 p.
This guideline presents updated World Health Organization recommendations on the use of antiplatelet agents for the prevention of pre-eclampsia, replacing the corresponding recommendations issued in 2011 in light of new evidence. It aims to support evidence-informed clinical practice and policy by providing guidance on the use and timing of low-dose acetylsalicylic acid (aspirin) for pregnant women at moderate or high risk of developing pre-eclampsia. The recommendations are intended for health professionals, programme managers, policy-makers and institutions involved in maternal and newborn health care across all settings. The guideline was developed following the WHO Handbook for Guideline Development using the GRADE approach and an updated systematic review of the available evidence. In addition to assessing the balance of benefits and harms, the Guideline Development Group considered the certainty of the evidence, women’s values and preferences, resource implications, cost-effectiveness, acceptability, feasibility and equity through an Evidence-to-Decision framework. The document includes implementation considerations, identifies research priorities and discusses issues related to dissemination, adaptation and future updating to facilitate effective and equitable implementation of the recommendations for improving maternal and perinatal health outcomes.
This guideline presents updated World Health Organization recommendations on the use of antiplatelet agents for the prevention of pre-eclampsia, replacing the corresponding recommendations issued in 2011 in light of new evidence. It aims to support evidence-informed clinical practice and policy by providing guidance on the use and timing of low-dose acetylsalicylic acid (aspirin) for pregnant women at moderate or high risk of developing pre-eclampsia. The recommendations are intended for health professionals, programme managers, policy-makers and institutions involved in maternal and newborn health care across all settings. The guideline was developed following the WHO Handbook for Guideline Development using the GRADE approach and an updated systematic review of the available evidence. In addition to assessing the balance of benefits and harms, the Guideline Development Group considered the certainty of the evidence, women’s values and preferences, resource implications, cost-effectiveness, acceptability, feasibility and equity through an Evidence-to-Decision framework. The document includes implementation considerations, identifies research priorities and discusses issues related to dissemination, adaptation and future updating to facilitate effective and equitable implementation of the recommendations for improving maternal and perinatal health outcomes.